We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.13 | 2.74% | 4.88 | 4.50 | 5.00 | 4.805 | 4.625 | 4.625 | 719,509 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -5.28 | 226.41M |
TIDMAGY
RNS Number : 1108T
Allergy Therapeutics PLC
30 December 2016
30 December 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.
Executive Director Number of Conditional Total conditional shares awarded shares held under LTIPs -------------------- ---------------------- ------------------- Manuel Llobet 1,690,000 3,380,000 -------------------- ---------------------- ------------------- Nick Wykeman 422,500 422,500 -------------------- ---------------------- -------------------
The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated ---- ------------------------------------------------------------ a) Name Manuel Llobet Nicolas Wykeman ---- ------------------- --------------------------------------- 2 Reason for the notification Grant of conditional awards of 0.1 pence each ---- ------------------------------------------------------------ a) Position/status Manual Llobet - Chief Executive Office Nicolas Wykeman - Finance Director ---- ------------------- --------------------------------------- b) Initial Initial notification notification /Amendment ---- ------------------- --------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ------------------------------------------------------------ a) Name ALLERGY THERAPEUTICS PLC ---- ------------------- --------------------------------------- b) LEI ---- ------------------- --------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ------------------------------------------------------------ a) Description Conditional award of shares under of the financial the Company's Long Term Incentive instrument, Plan type of instrument Identification code ---- ------------------- --------------------------------------- b) Nature of the transaction ---- ------------------- --------------------------------------- Price(s) c) and volume(s) 1,690,000 ---- ------------------- --------------------------------------- d) Aggregated information - Aggregated volume - Price ---- ------------------- --------------------------------------- e) Date of 30 December 2016 the transaction ---- ------------------- --------------------------------------- f) Place of Outside a trading venue the transaction ---- ------------------- ---------------------------------------
Name of authorised official of issuer responsible for making notification:
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Nick Wykeman, Finance Director Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking Consilium Strategic Communications +44 20 3709 5700 Mary-Jane Elliott / Ivar Milligan allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHZBLFXQLFLFBD
(END) Dow Jones Newswires
December 30, 2016 09:31 ET (14:31 GMT)
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions